35. Update on TB Diagnostics and Treatment of Complex, Multidrug-Resistant TB
Friday, October 21, 2011: 8:45 AM-10:15 AM
Room: 253ABC

Learning Objectives:

At the conclusion of this session, participants will be able to identify: 

  • the appropriate use of new clinical diagnostic tests for tuberculosis (TB)
  • the appropriate management of complex, drug-resistant TB, including the role of surgery
  • recognize the key features of new drugs for TB under development

Target Audience: Scientists, Researchers, Public Health Practitioners, Pharmacists, Nurses, Microbiologists, Lab Personnel, Investigators, Infectious Diseases Physicians, Infectious Diseases Pediatricians, Infection Preventionists, Hospital Epidemiologists, Hospital Administrators, HIV Clinicians, Health Care Workers, Fellows-in-Training, Epidemiologists, Clinicians, Academicians

Tracks: Global ID, Investigative ID, Pediatric ID, Adult ID

Moderators:  Robert Read, MD, FIDSA, University of Sheffield and Sheffield Teaching Hospitals Sheffield and Kenneth G. Castro, MD, Centers for Disease Control and Prevention

CME Credits: Maximum of 1.5 hours of Category 1 credit possible

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of Pharmacy CE

ACPE Number: 0461-9999-11-127-L01-P


R. Read, None

K. G. Castro, None

M. Salfinger, None

G. Huitt, Hill-Rom: Scientific Advisor and Speaker's Bureau, Consulting fee and Speaker honorarium

B. Seaworth, Otsuka Pharmaceuticals: Investigator and Study 204, phase II trial of IND for TB-complete, F/U record review in progress, Research support
HHSC Advisory Committe for Elimination of TB: Scientific Advisor, None

E. Nuermberger, sanofi-aventis: Grant Investigator, Research support
Pfizer: Grant Investigator, Research grant

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.